Search results
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Zacks via Yahoo Finance· 4 days agoTakeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling...
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Reuters via Yahoo Finance· 3 days agoWith this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines ...
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
Pharmaceutical Technology via Yahoo Finance· 2 days agoNeurocine has been in the news recently for its other therapies such as NBI-1065845, a treatment for...
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Investor's Business Daily· 2 days agoAbrahams says Neurocrine's depression treatment has a 40% chance of winning approval and a $2.3...
Cell and gene therapy companies trip at scalability hurdle
Pharmaceutical Technology via Yahoo Finance· 4 days agoEven larger companies were not exempt, with Takeda Pharmaceuticals discontinuing its early research...
Anxiety Disorder Treatment Market Towards US$ 15.89 Bn by 2030 | Rising Mental Health Awareness and...
Digital Journal· 7 days agoThe global anxiety disorder treatment market size is projected to grow from $12 billion in 2022 to...
Why are nearly half of all recent biotech RNA alliances in Asia-Pacific betting big on...
BioPharma-Reporter· 3 days agoAlmost half of all strategic alliances focused on RNA therapies over the last five years in the...
Atlanta Community Food Bank opens new location in Jonesboro
WXIA-TV Atlanta· 2 days agoA new resource for Clayton County families experiencing food insecurity has officially opened its...
Type 1 Diabetes Market Expected to Reach USD 13.64 Billion by 2030 Predicts SNS Insider | Leading...
Digital Journal· 7 days agoThe global Type 1 Diabetes Market, which was valued at USD 7.59 billion in 2022, is anticipated to...